Many of the 2016 updated EULAR recommendations for the management of gout lack robust evidence and rely on expert opinion, indicating gaps in our understanding of this common disease. More research is needed to fill these gaps, move towards an evidence-based approach, and improve patient care.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kuo, C. F., Grainge, M. J., Zhang, W. & Doherty, M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11, 649–662 (2015).
Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care. Res. 64, 1447–1461 (2012).
Richette, P. et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-209707 (2016).
van der Heijde, D. et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann. Rheum. Dis. 74, 8–13 (2015).
Spencer, K., Carr, A. & Doherty, M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann. Rheum. Dis. 7, 1490–1495 (2012).
Kuo, C. F., Grainge, M. J., Mallen, C., Zhang, W. & Doherty, M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann. Rheum. Dis. 74, 661–667 (2015).
Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their extensions. Ann. Rheum. Dis. 71, 1839–1848 (2012).
Wortmann, R. L., Macdonald, P. A., Hunt, B. & Jackson, R. L. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials. Clin. Ther. 32, 2386–2397 (2010).
Schlesinger, I. & Schlesinger, N. Uric acid in Parkinson's disease. Mov. Disord. 23, 1653–1657 (2008).
European Medicines Agency. Krystexxa. Withdrawal of the marketing authorization in the European Union. European Medicines Agency http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2016/07/WC500210911.pdf (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares that she has received grants from AstraZeneca; is a member of the advisory boards for Pfizer, AstraZeneca, ProteoThera, Celgene and Horizon Pharma; is a member of a speakers' bureau for Novartis and Takeda; and is a consultant for Novartis, Sobi and BMS.
Rights and permissions
About this article
Cite this article
Schlesinger, N. New recommendations highlight the need for more research. Nat Rev Rheumatol 12, 628–630 (2016). https://doi.org/10.1038/nrrheum.2016.150
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.150
